Provided by Tiger Trade Technology Pte. Ltd.

Allogene Therapeutics Inc.

1.99
-0.0300-1.49%
Volume:1.84M
Turnover:3.66M
Market Cap:686.55M
PE:-3.06
High:2.02
Open:2.01
Low:1.96
Close:2.02
52wk High:4.46
52wk Low:1.04
Shares:345.00M
Float Shares:262.00M
Volume Ratio:0.88
T/O Rate:0.70%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.6510
EPS(LYR):-0.8652
ROE:-42.39%
ROA:-22.08%
PB:1.57
PE(LYR):-2.30

Loading ...

Allogene Therapeutics to Present at Citi Biopharma Back to School Conference

Reuters
·
Yesterday

Analysts Offer Insights on Healthcare Companies: Silence Therapeutics (SLN), Cardinal Health (CAH) and Allogene Therapeutics (ALLO)

TIPRANKS
·
Aug 17

Allogene Therapeutics Remains Attractive Given Valuation, Clinical Strategy, RBC Says

MT Newswires Live
·
Aug 13

Allogene Therapeutics, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 13

Allogene Therapeutics Q2 Loss Narrows

MT Newswires Live
·
Aug 13

Earnings Flash (ALLO) Allogene Therapeutics Posts Q2 Loss $0.13 per Share, vs. FactSet Est of $0.17 Loss

MT Newswires Live
·
Aug 13

Allogene Therapeutics - May Offer up to $500 Mln in Securities - SEC Filing

THOMSON REUTERS
·
Aug 13

Allogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update

THOMSON REUTERS
·
Aug 13

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Aug 11

Allogene Therapeutics, Inc. Expected to Post a Loss of 17 Cents a Share - Earnings Preview

Reuters
·
Aug 11

Press Release: Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Dow Jones
·
Aug 07

Allogene Therapeutics Schedules Quarterly Results, Business Update Call

Reuters
·
Aug 04

Allogene Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update

THOMSON REUTERS
·
Aug 04

Analysts’ Top Healthcare Picks: Repligen (RGEN), Allogene Therapeutics (ALLO)

TIPRANKS
·
Jul 30

Allogene gets RMAT, Fast Track designations for cemacabtagene ansegedleucel

TIPRANKS
·
Jul 29

Allogene Cema-cel Posts 58.3% MRD Clearance in Alpha3 First-line LBCL Consolidation Study

Reuters
·
Jul 29

Allogene Therapeutics - no Treatment-Related Serious Adverse Events or High-Grade Infections Reported for Cema-Cel

THOMSON REUTERS
·
Jul 29

Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (Rmat) Designation for Cemacabtagene Ansegedleucel (Cema-Cel) as First-Line Consolidation Therapy for Large B-Cell Lymphoma

THOMSON REUTERS
·
Jul 29

Allogene publishes Phase 1 data in Journal of Clinical Oncology

TIPRANKS
·
Jul 15

Allogene Says Phase 1 Trial Shows 31% Response Rate for Allo-316 in Cd70-high Metastatic Kidney Cancer

Reuters
·
Jul 15